<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>FDA发行第一批Covid-19疫苗的紧急使用授权 FDA Issuing Emergency Use Authorization for First Covid-19 Vaccine</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">FDA Issuing Emergency Use Authorization for First Covid-19 Vaccine<br/>FDA发行第一批Covid-19疫苗的紧急使用授权 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-12-12 11:18:00</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2020/12/6546b10e51e1e1e6cd91a3c94333830f.png"><img src="http://img2.diglog.com/img/2020/12/6546b10e51e1e1e6cd91a3c94333830f.png" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>Today, the U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S.</p><p>今天，美国食品药品监督管理局（FDA）首次发布了预防由严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）引起的2019年冠状病毒疾病疫苗（SARS-CoV-2）的紧急使用授权（EUA）16岁以上。紧急使用授权允许将Pfizer-BioNTech COVID-19疫苗分配到美国。</p><p> “The FDA’s authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world,” said FDA Commissioner Stephen M. Hahn, M.D. “Today’s action follows an open and transparent review process that included input from independent scientific and public health experts and a thorough evaluation by the agency’s career scientists to ensure this vaccine met FDA’s rigorous, scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization. The tireless work to develop a new vaccine to prevent this novel, serious, and life-threatening disease in an expedited timeframe after its emergence is a true testament to scientific innovation and public-private collaboration worldwide.”</p><p> FDA专员Stephen M. Hahn医师表示：“ FDA紧急使用首批COVID-19疫苗的授权，是抗击这场毁灭性大流行的重要里程碑，这种大流行已影响到美国和世界各地的许多家庭。”采取行动之前，采取了公开透明的审查程序，其中包括来自独立科学和公共卫生专家的意见，并由该机构的职业科学家进行了全面评估，以确保该疫苗符合支持紧急使用所需的FDA严格的安全性，有效性和生产质量科学标准。授权。研发出一种新疫苗来预防这种新颖，严重，威胁生命的疾病，在其出现后的不懈努力下不懈地努力，这是对全球科学创新和公私合作的真实证明。”</p><p> The FDA has determined that Pfizer-BioNTech COVID-19 Vaccine has met the statutory criteria for issuance of an EUA. The totality of the available data provides clear evidence that Pfizer-BioNTech COVID-19 Vaccine may be effective in preventing COVID-19. The data also support that the known and potential benefits outweigh the known and potential risks, supporting the vaccine’s use in millions of people 16 years of age and older, including healthy individuals. In making this determination, the FDA can assure the public and medical community that it has conducted a thorough evaluation of the available safety, effectiveness and manufacturing quality information.</p><p> FDA确定Pfizer-BioNTech COVID-19疫苗已符合签发EUA的法定标准。可用数据的总数提供了明确的证据，证明辉瑞BioNTech COVID-19疫苗可能有效预防COVID-19。数据还支持已知和潜在的利益大于已知和潜在的风险，从而支持疫苗在16岁及以上的数百万人中使用，包括健康个体。在做出此决定时，FDA可以向公众和医学界保证，它已经对可用的安全性，有效性和制造质量信息进行了彻底的评估。</p><p> The Pfizer-BioNTech COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. The vaccine contains a small piece of the SARS-CoV-2 virus’s mRNA that instructs cells in the body to make the virus’s distinctive “spike” protein. When a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2.</p><p> 辉瑞BioNTech COVID-19疫苗含有信使RNA（mRNA），这是遗传物质。该疫苗含有一小段SARS-CoV-2病毒的mRNA，可指示体内细胞产生该病毒的独特“尖峰”蛋白。当一个人收到这种疫苗时，他们的身体会产生刺突蛋白的拷贝，该蛋白不会引起疾病，但会触发免疫系统学习防御性反应，从而产生针对SARS-CoV-2的免疫反应。</p><p> “While not an FDA approval, today’s emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine holds the promise to alter the course of this pandemic in the United States,” said Peter Marks, M.D., Ph.D., Director of the FDA’s Center for Biologics Evaluation and Research. “With science guiding our decision-making, the available safety and effectiveness data support the authorization of the Pfizer-BioNTech COVID-19 Vaccine because the vaccine’s known and potential benefits clearly outweigh its known and potential risks. The data provided by the sponsor have met the FDA’s expectations as conveyed in our June and October guidance documents. Efforts to speed vaccine development have not sacrificed scientific standards or the integrity of our vaccine evaluation process. The FDA’s review process also included public and independent review from members of the agency’s Vaccines and Related Biological Products Advisory Committee. Today’s achievement is ultimately a testament to the commitment of our career scientists and physicians, who worked tirelessly to thoroughly evaluate the data and information for this vaccine.”</p><p> “尽管没有获得FDA的批准，但辉瑞-BioNTech COVID-19疫苗今天的紧急使用授权仍有望改变美国大流行的过程，”医学博士Peter Marks博士说FDA的生物制品评估和研究中心。 “在科学指导我们的决策的情况下，可用的安全性和有效性数据可支持辉瑞BioNTech COVID-19疫苗的授权，因为该疫苗的已知和潜在好处明显大于其已知和潜在风险。赞助商提供的数据已达到我们在6月和10月指导文件中传达的FDA期望。加速疫苗开发的努力并未牺牲科学标准或我们疫苗评估过程的完整性。 FDA的审查程序还包括该机构疫苗和相关生物产品咨询委员会成员的公开和独立审查。今天的成就最终证明了我们的职业科学家和医师的不懈努力，他们孜孜不倦地致力于彻底评估这种疫苗的数据和信息。”</p><p>  Pfizer BioNTech COVID-19 Vaccine is administered as a series of two doses, three weeks apart. The available safety data to support the EUA include 37,586 of the participants enrolled in an ongoing randomized, placebo-controlled international study, the majority of whom are U.S. participants. These participants, 18,801 of whom received the vaccine and 18,785 of whom received saline placebo, were followed for a median of two months after receiving the second dose. The most commonly reported side effects, which typically lasted several days, were pain at the injection site, tiredness, headache, muscle pain, chills, joint pain, and fever. Of note, more people experienced these side effects after the second dose than after the first dose, so it is important for vaccination providers and recipients to expect that there may be some side effects after either dose, but even more so after the second dose.</p><p>  辉瑞BioNTech COVID-19疫苗分两次给药，间隔三周。支持EUA的可用安全性数据包括正在进行的随机，安慰剂对照国际研究中的37,586名参与者，其中大多数是美国参与者。这些参与者中，有18,801人接受了疫苗，其中18,785人接受了生理盐水安慰剂，在接受第二剂疫苗后进行了两个月的中位随访。最常报告的副作用（通常持续几天）是注射部位的疼痛，疲倦，头痛，肌肉疼痛，发冷，关节痛和发烧。值得注意的是，与第二剂相比，第二剂后更多的人经历了这些副作用，因此对于疫苗接种提供者和接受者来说，重要的是要期望在任一剂后都有某些副作用，而在第二剂后甚至更多。</p><p> It is mandatory for Pfizer Inc. and vaccination providers to report the following to the Vaccine Adverse Event Reporting System (VAERS) for Pfizer-BioNTech COVID-19 Vaccine: all vaccine administration errors, serious adverse events, cases of Multisystem Inflammatory Syndrome (MIS), and cases of COVID-19 that result in hospitalization or death.</p><p> 辉瑞公司和疫苗接种提供者必须向辉瑞BioNTech COVID-19疫苗的疫苗不良事件报告系统（VAERS）报告以下内容：所有疫苗管理错误，严重的不良事件，多系统炎症综合症（MIS）病例，以及导致住院或死亡的COVID-19病例。 </p><p>  The effectiveness data to support the EUA include an analysis of 36,523 participants in the ongoing randomized, placebo-controlled international study, the majority of whom are U.S. participants, who did not have evidence of SARS-CoV-2 infection through seven days after the second dose. Among these participants, 18,198 received the vaccine and 18,325 received placebo. The vaccine was 95% effective in preventing COVID-19 disease among these clinical trial participants with eight COVID-19 cases in the vaccine group and 162 in the placebo group. Of these 170 COVID-19 cases, one in the vaccine group and three in the placebo group were classified as severe. At this time, data are not available to make a determination about how long the vaccine will provide protection, nor is there evidence that the vaccine prevents transmission of SARS-CoV-2 from person to person.</p><p>支持EUA的有效性数据包括对正在进行的随机，安慰剂对照国际研究中的36,523名参与者的分析，其中大多数是美国参与者，他们在第二次随访后的7天内没有SARS-CoV-2感染的证据剂量。在这些参与者中，有18,198人接受了疫苗，有18,325人接受了安慰剂。在这些临床试验参与者中，该疫苗在预防COVID-19疾病方面有95％的有效率，疫苗组有8例COVID-19病例，安慰剂组有162例。在这170例COVID-19病例中，疫苗组1例，安慰剂组3例被分类为严重。目前，尚无数据可确定疫苗将提供多长时间的保护，也没有证据表明疫苗可防止人与人之间传播SARS-CoV-2。</p><p>  On the basis of the determination by the Secretary of the Department of Health and Human Services on February 4, 2020, that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and then issued declarations that  circumstances exist justifying the authorization of emergency use of unapproved products, the FDA may issue an EUA to allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent COVID-19 when there are no adequate, approved, and available alternatives.</p><p>  根据卫生与公共服务部部长于2020年2月4日确定的紧急公共卫生事件，该事件可能会严重影响国家安全或居住在国外的美国公民的健康与安全，然后发布声明，指出存在可以批准紧急使用未经批准的产品的理由，FDA可能会发布EUA，以允许未经批准的医疗产品或未经批准的批准使用的医疗产品用于紧急情况以诊断，治疗或预防COVID -19，如果没有足够的，已批准的和可用的替代方法。</p><p> The issuance of an EUA is different than an FDA approval (licensure) of a vaccine. In determining whether to issue an EUA for a product, the FDA evaluates the available evidence and assesses any known or potential risks and any known or potential benefits, and if the benefit-risk assessment is favorable, the product is made available during the emergency. Once a manufacturer submits an EUA request for a COVID-19 vaccine to the FDA, the agency then evaluates the request and determines whether the relevant statutory criteria are met, taking into account the totality of the scientific evidence about the vaccine that is available to the FDA.</p><p> EUA的签发与FDA疫苗的批准（许可）不同。在确定是否为产品签发EUA时，FDA评估可用证据并评估任何已知或潜在风险以及任何已知或潜在利益，如果利益风险评估是有利的，则在紧急情况下可以使用该产品。一旦制造商向FDA提交EUA要求COVID-19疫苗的申请，该机构便会评估该要求并确定是否满足相关法定标准，同时考虑到可用于该疫苗的科学证据的总数。 FDA。</p><p> The EUA also requires that fact sheets that provide important information, including dosing instructions, and information about the benefits and risks of the Pfizer-BioNTech COVID-19 Vaccine, be made available to vaccination providers and vaccine recipients.</p><p> EUA还要求将提供重要信息（包括剂量说明）以及有关Pfizer-BioNTech COVID-19疫苗的益处和风险的信息的情况说明书提供给疫苗提供者和疫苗接受者。</p><p> The company has submitted a pharmacovigilance plan to FDA to monitor the safety of Pfizer-BioNTech COVID-19 Vaccine. The pharmacovigilance plan includes a plan to complete longer-term safety follow-up for participants enrolled in ongoing clinical trials. The pharmacovigilance plan also includes other activities aimed at monitoring the safety profile of the Pfizer-BioNTech COVID-19 vaccine and ensuring that any safety concerns are identified and evaluated in a timely manner.</p><p> 该公司已向FDA提交了药物警戒计划，以监测辉瑞BioNTech COVID-19疫苗的安全性。药物警戒计划包括一项计划，该计划针对正在进行的临床试验中的参与者完成长期安全性随访。药物警戒计划还包括其他活动，旨在监测辉瑞-BioNTech COVID-19疫苗的安全性，并确保及时发现和评估任何安全隐患。</p><p> The FDA also expects manufacturers whose COVID-19 vaccines are authorized under an EUA to continue their clinical trials to obtain additional safety and effectiveness information and pursue approval (licensure).</p><p> FDA还希望获得EUA授权其COVID-19疫苗的制造商继续其临床试验，以获得更多的安全性和有效性信息并寻求批准（许可）。</p><p> The EUA for the Pfizer-BioNTech COVID-19 Vaccine was issued to Pfizer Inc. The EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biologics for prevention and treatment of COVID-19 is terminated, and may be revised or revoked if it is determined the EUA no longer meets the statutory criteria for issuance.</p><p> 辉瑞公司已将Pfizer-BioNTech COVID-19疫苗的EUA签发。EUA将一直有效，直到宣布存在足以证明可以紧急使用药物和生物制剂预防和治疗COVID-19的授权的声明为止。如果确定EUA不再符合法定的发行标准，则可以进行修订或撤销。 </p><p> The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.</p><p>FDA是美国卫生与公共服务部的一个机构，它通过确保人用和兽用药物，疫苗和其他人类用生物制品以及医疗设备的安全性，有效性和安全性来保护公众健康。 该机构还负责国家食品，化妆品，膳食补充剂，释放电子辐射的产品以及管制烟草产品的安全。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19">https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/fda/">#fda</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/issuing/">#issuing</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>